Biopharmaceutical company Palatin Technologies, Inc. (PTN) announced Tuesday that it is developing PL8177 as a treatment for patients with COVID-19, and having hypoxemic respiratory failure with or without acute respiratory distress syndrome (ARDS).
from RTT - Biotech https://ift.tt/3dmsSfr
via IFTTT
No comments:
Post a Comment